> Detailanzeige

Penack, Olaf; Dreger, Peter; Ajib, Salem; Ayuk, Francis; Baermann, Ben-Niklas; Bug, Gesine; Kriege, Oliver; Jentzsch, Madlen; Kobbe, Guido; Koenecke, Christian; Lutz, Mathias; Martin, Sonja; Schlegel, Paul-Gerhard; Schroers, Roland; von Tresckow, Bastian; Vucinic, Vladan; Subklewe, Marion; Bethge, Wolfgang; Wolff, Daniel

Management of Patients Undergoing CAR-T Cell Therapy in Germany

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Management of Patients Undergoing CAR-T Cell Therapy in Germany
  • Beteiligte: Penack, Olaf; Dreger, Peter; Ajib, Salem; Ayuk, Francis; Baermann, Ben-Niklas; Bug, Gesine; Kriege, Oliver; Jentzsch, Madlen; Kobbe, Guido; Koenecke, Christian; Lutz, Mathias; Martin, Sonja; Schlegel, Paul-Gerhard; Schroers, Roland; von Tresckow, Bastian; Vucinic, Vladan; Subklewe, Marion; Bethge, Wolfgang; Wolff, Daniel
  • Erschienen: S. Karger AG, 2024
  • Erschienen in: Oncology Research and Treatment
  • Sprache: Englisch
  • DOI: 10.1159/000536201
  • ISSN: 2296-5270; 2296-5262
  • Schlagwörter: Cancer Research ; Oncology ; Hematology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no – or low quality – clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome. </jats:p>